KESIMPTA: Novartis Pharmacuticals Corporation

 Kesimpta

Generic Name: Ofatumumab 

Dosage Form: Injection for subcutaneous use. 

FDA Approval Date: August 25, 2020

The Kesimpta is a prescription medicine used to treat adults with relapsing form of multiple sclerosis. It is mainly used for clinically isolated syndrome, relapsing remitting diseases and active secondary progressive diseases. 

Therapeutic Use: 

Multiple Sclerosis

Side Effects: 

Serious infection can occur during treatment with kesimpta. If patient is having active infection then health care provider should first normalize the infection then kesimpta should be given. 

When kesimpta is taken before or after the drug that weakens immune system then these causes higher risk of infection. 

Before taking kesimpta the healthcare provider will do blood test for HBV. If patient in past was having infection with HBV then these may get active again. 

Progressive multifocal  leukoencephelopathy can occur with kesimpta. 

Storage Condition: 

Store kesimpta in refrigerator. 

Do not freeze and do not shake.